NCT05461235View on ClinicalTrials.gov

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

July 15, 2025

Study Completion Date

December 1, 2025

Conditions
PD-1 AntibodyDC-CellNK-CellGastrointestinal Tumours
Interventions
DRUG

Pembrolizumab

2mg/kg or 200mg,iv,q3w

DRUG

Nivolumab

3mg/kg or 240mg,iv,q2w

DRUG

Sintilimab

200mg,iv,q3w

DRUG

Toripalimab

3mg/kg or 240mg,iv,q2w

DRUG

Camrelizumab

200mg,iv,q2w or q3w;3mg/kg,iv,q3w

DRUG

Tislelizumab

200mg,iv,q3w

BIOLOGICAL

NK-Cell or DC-Cell

50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.

All Listed Sponsors
lead

China Medical University, China

OTHER

NCT05461235 - Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | Biotech Hunter | Biotech Hunter